[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Moves -1.73%: What You Should Know",
    "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $201.64, denoting a -1.73% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=7d7485b7169bd80c41431d7db6a98b45f34e94b370d9b9754db4e1f2f7c6b44b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743716715,
      "headline": "AbbVie (ABBV) Stock Moves -1.73%: What You Should Know",
      "id": 133704643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $201.64, denoting a -1.73% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=7d7485b7169bd80c41431d7db6a98b45f34e94b370d9b9754db4e1f2f7c6b44b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie cuts 2025 profit forecast on acquisition expenses",
    "summary": "AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and development costs. The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection in 2023. To that end, the company bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total.",
    "url": "https://finnhub.io/api/news?id=5aec81b9c68b8753c08f0570ef323a33fa24f2997bd1c6bf6390efb6c611d011",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743712488,
      "headline": "AbbVie cuts 2025 profit forecast on acquisition expenses",
      "id": 133704645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and development costs. The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection in 2023. To that end, the company bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total.",
      "url": "https://finnhub.io/api/news?id=5aec81b9c68b8753c08f0570ef323a33fa24f2997bd1c6bf6390efb6c611d011"
    }
  },
  {
    "ts": null,
    "headline": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
    "summary": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
    "url": "https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743705780,
      "headline": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
      "id": 133705356,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",
      "url": "https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
    "summary": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
    "url": "https://finnhub.io/api/news?id=9201434bddd814d56ee9eeb219358f350bdede42fd82155c651e1734a1f6d4b9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743697611,
      "headline": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
      "id": 133705729,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.",
      "url": "https://finnhub.io/api/news?id=9201434bddd814d56ee9eeb219358f350bdede42fd82155c651e1734a1f6d4b9"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About",
    "summary": "\"Buy and hold\" is a simple strategy for investors, but it can be a hard one to stick to in actual practice.  Not every long-term investment will turn out that way, but investing a modest amount of money in growth stocks and letting it sit can be your best financial move.  Retirees on the lookout for some reliable dividend stocks can find plenty of attractive buying opportunities in the markets today.",
    "url": "https://finnhub.io/api/news?id=621bf6894c00c3adc0c8be3f11f1436d2e72ba14b91dd387f0a18122277e324c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743685200,
      "headline": "3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About",
      "id": 133697706,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "\"Buy and hold\" is a simple strategy for investors, but it can be a hard one to stick to in actual practice.  Not every long-term investment will turn out that way, but investing a modest amount of money in growth stocks and letting it sit can be your best financial move.  Retirees on the lookout for some reliable dividend stocks can find plenty of attractive buying opportunities in the markets today.",
      "url": "https://finnhub.io/api/news?id=621bf6894c00c3adc0c8be3f11f1436d2e72ba14b91dd387f0a18122277e324c"
    }
  }
]